Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis Source: Eur Respir J 2007; 30: Suppl. 51, 528s Year: 2007
Effects of long term low dose azithromycin in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010
Usefulness of long term treatment with azithromycin in patients with bronchiectasis (non cystic fibrosis) Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Assessing response to treatment of exacerbations of bronchiectasis in adults Source: Eur Respir J 2009; 33: 312-318 Year: 2009
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005
Doxycycline improves clinical outcomes during cystic fibrosis exacerbations Source: Eur Respir J , 49 (4) 1601102; DOI: 10.1183/13993003.01102-2016 Year: 2017
Demographics and characteristics of antibiotic use in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – From pleura to bronchi: new insights Year: 2016
Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004
Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005
Role of non-cystic fibrosis bronchiectasis in hospitalized patients with acute exacerbation of COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017
Inhaled steroids in children with non-cystic fibrosis bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 392s Year: 2004
The potential impact of azithromycin in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018 Year: 2019
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016
Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017
Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016
Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019